Methods and Compositions for Inducing an Immune Response Against Hepatitis B Virus (HBV)
AssigneesJanssen Sciences Ireland Unlimited Company, Bavarian Nordic A/S
InventorsDaniel BODEN, Helen HORTON, Jean-Marc Edmond Fernand Marie NEEFS, Soumitra ROY, Jerôme Hubertina Henricus Victor CUSTERS, Roland Christian ZAHN, Markus KALLA
Life of this patent
Estimating the term…
Abstract
Provided herein are Modified Vaccinia Ankara (MVA) vectors and adenovirus vectors encoding HBV antigens. Also provided are methods of enhancing an immune response in a human subject by utilizing the MVA and adenovirus vectors encoding HBV antigens in a prime/boost regimen to the enhance the immune response in the human subject.
Claims20
A method of enhancing an immune response in a human subject, the method comprising:
- (a) administering to the human subject a first composition comprising an immunologically effective amount of an adenovirus vector comprising a non-naturally occurring nucleic acid molecule comprising a first polynucleotide sequence encoding an HBV polymerase antigen comprising an amino acid sequence that is at least 98% identical to SEQ ID NO:4;
- and
- (b) administering to the human subject a second composition comprising an immunologically effective amount of a Modified Vaccinia Ankara (MVA) vector comprising a non-naturally occurring nucleic acid molecule comprising a first polynucleotide sequence encoding an HBV polymerase antigen comprising an amino acid sequence that is at least 98% identical to SEQ ID NO:
- 4;
- to thereby obtain an enhanced immune response against the HBV antigen in the human subject.
A method of enhancing an immune response in a human subject, the method comprising:
- (a) administering to the human subject a first composition comprising an immunologically effective amount of a first plasmid comprising a first non-naturally occurring nucleic acid molecule comprising a first polynucleotide sequence encoding an HBV polymerase antigen comprising an amino acid sequence that is at least 98% identical to SEQ ID NO:
- 4;
- and
- (b) administering to the human subject a second composition comprising an immunologically effective amount of a Modified Vaccinia Ankara (MVA) vector comprising a non-naturally occurring nucleic acid molecule comprising a first polynucleotide sequence encoding an HBV polymerase antigen comprising an amino acid sequence that is at least 98% identical to SEQ ID NO:
- 4;
- to thereby obtain an enhanced immune response against the HBV antigen in the human subject.
Dependencies are inferred from the claim text.